Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | IL2 | P60568 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25204552 | 0.94 | TTR (0.46) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL20016562 | 0.94 | TTR (0.45) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL24335147 | 0.92 | TTR (0.43) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL26412265 | 0.91 | TTR (0.42) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL12342504 | 0.91 | TTR (0.44) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL31681640 | 0.88 | TTR (0.44) | TTRIL2FOLH1PLGOPRM1 | |
| SCHEMBL22969740 | 0.86 | TTR (0.38) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL22388613 | 0.86 | KLKB1 (0.37) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL22452311 | 0.85 | TTR (0.37) | TTRIL2KLKB1FOLH1PLG | |
| SCHEMBL23180460 | 0.85 | TTR (0.37) | TTRIL2KLKB1FOLH1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 895 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746921-A1 | DRUG CONJUGATES OF IMIDAZOQUINOLINE AMINE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Canwell Biotech Limited (CN) | 2026-05-27 | — | — | EP | claimed |
| WO-2026098715-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING ANTI-CLDN6 ANTIBODY | 智泽童康(广州)生物科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | HALOZYME, INC. (US) | 2026-03-12 | — | — | US | claimed |
| US-20260048137-A1 | ANTI-MESOTHELIN ANTIBODY CONJUGATES AND METHODS OF USE THEREOF | ARDEAGEN CORP (US) | 2026-02-19 | — | — | US | claimed |
| EP-4688000-A1 | ANTIBODY DRUG CONJUGATES | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | claimed |
| US-20250332184-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | IMMUNOMEDICS INC (US) | 2025-10-30 | — | — | US | claimed |
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| US-20250312328-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | IMMUNOMEDICS, INC. | 2025-10-09 | — | — | US | claimed |
| WO-2022082066-A1 | ANTI-CSPG4 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | ARDEAGEN CORPORATION (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022082068-A1 | ANTI-MSLN BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USING THE SAME | ARDEAGEN CORPORATION (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114222734-A | Method for preparing substituted chromanone derivative | 杭州杜易科技有限公司 | 2022-03-22 | — | — | CN | claimed |
| WO-2022048860-A1 | METHOD AND SYSTEM FOR COMMUNICATION BETWEEN CLIENTS IN A DISTRIBUTED INDUSTRIAL ENVIRONMENT | SIEMENS AKTIENGESELLSCHAFT (DE) | 2022-03-10 | — | — | WO | claimed |
| EP-3965387-A1 | METHOD AND SYSTEM FOR COMMUNICATION BETWEEN CLIENTS IN A DISTRIBUTED INDUSTRIAL ENVIRONMENT | Siemens Aktiengesellschaft (DE) | 2022-03-09 | — | — | EP | claimed |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | IMMUNOMEDICS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| EP-2900277-B1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS INC (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3954373-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | Immunomedics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| US-11242407-B2 | High-affinity anti-MERTK antibodies and uses thereof | INSPIRNA, INC. (US) | 2022-02-08 | — | — | US | claimed |
| CN-110808533-B | High-temperature ICP (inductively coupled plasma) etching method for aluminum-containing material in high-speed DFB (distributed feed Back) chip | 湖北光安伦芯片有限公司 | 2022-01-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048137-A1 | ANTI-MESOTHELIN ANTIBODY CONJUGATES AND METHODS OF USE THEREOF | MST1R, MDN1, MBNL1 | TTR 1131/4885IL2 3749/4885KLKB1 2531/4885 |
| US-20250332184-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | ENTPD1, ENTPD2, ENTPD8 | TTR 3979/4885IL2 519/4885KLKB1 2170/4885 |
| US-20250312328-A1 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EPCAM, CD47, CD2 | TTR 1278/4885IL2 160/4885KLKB1 1857/4885 |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | CD22, CD2, CD44 | TTR 284/4885IL2 257/4885KLKB1 1023/4885 |
| US-11253606-B2 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | PARP2, DOCK2, DYNLL2 | TTR 4293/4885IL2 339/4885KLKB1 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.